Amedisys, Inc. (NASDAQ:AMED) Shares Purchased by Amalgamated Bank

Amalgamated Bank raised its stake in shares of Amedisys, Inc. (NASDAQ:AMED) by 2.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 15,593 shares of the health services provider’s stock after acquiring an additional 444 shares during the period. Amalgamated Bank’s holdings in Amedisys were worth $1,416,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AMED. Westchester Capital Management LLC raised its holdings in shares of Amedisys by 9.5% in the 3rd quarter. Westchester Capital Management LLC now owns 1,118,802 shares of the health services provider’s stock valued at $107,976,000 after purchasing an additional 97,476 shares in the last quarter. Geode Capital Management LLC increased its stake in Amedisys by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider’s stock valued at $54,746,000 after buying an additional 7,071 shares during the period. Pacer Advisors Inc. raised its holdings in Amedisys by 11,621.9% during the fourth quarter. Pacer Advisors Inc. now owns 558,197 shares of the health services provider’s stock worth $50,679,000 after purchasing an additional 553,435 shares in the last quarter. Calamos Advisors LLC lifted its holdings in shares of Amedisys by 22.7% in the 4th quarter. Calamos Advisors LLC now owns 487,444 shares of the health services provider’s stock valued at $44,255,000 after buying an additional 90,097 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in Amedisys by 2.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 346,082 shares of the health services provider’s stock worth $33,400,000 after buying an additional 9,004 shares during the period. Hedge funds and other institutional investors own 94.36% of the company’s stock.

Analysts Set New Price Targets

Separately, Stephens restated an “equal weight” rating and set a $101.00 target price on shares of Amedisys in a research report on Wednesday, February 12th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $100.75.

Amedisys Stock Performance

Amedisys stock opened at $92.00 on Tuesday. Amedisys, Inc. has a 12 month low of $82.15 and a 12 month high of $98.95. The company has a fifty day moving average price of $91.55 and a two-hundred day moving average price of $93.10. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The company has a market cap of $3.01 billion, a PE ratio of 36.51, a P/E/G ratio of 1.78 and a beta of 0.73.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Wednesday, February 26th. The health services provider reported $0.96 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.09). The business had revenue of $598.05 million during the quarter, compared to the consensus estimate of $602.38 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. Research analysts expect that Amedisys, Inc. will post 4.4 earnings per share for the current year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.